Acura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
11 sept. 2017 06h30 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced the results from the...
Acura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
31 août 2017 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones,...
Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results
14 août 2017 16h15 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for...
Acura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017
03 août 2017 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company...
Acura Pharmaceuticals Raises $4.0 Million in a Private Placement
24 juil. 2017 16h42 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., July 24, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that it has completed...
Acura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
28 juin 2017 16h10 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., June 28, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the results from...
Acura Pharmaceutical Initiates Second Clinical Study on LTX-04
18 mai 2017 16h10 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., May 18, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has...
Acura Pharmaceuticals Announces First Quarter 2017 Financial Results
12 mai 2017 16h15 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., May 12, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial...
Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
31 mars 2017 16h01 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., March 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial...
Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products
17 mars 2017 06h15 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, Ill., March 17, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR) and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement (the...